Please assess the completion status of the following clinical trial:

Trial Title: Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* \>= 18 years of age~* Stage IIIc or Stage IV BRAF V600E/K cutaneous melanoma~* Measurable disease according to RECIST 1.1~* Women of childbearing potential with negative serum pregnancy test prior to randomisation~* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1~* Adequate baseline organ function~Key Exclusion Criteria:~* Any prior use of a BRAF or MEK inhibitor~* Prior systemic anti-cancer treatment in the advanced or metastatic setting; prior systemic treatment in the adjuvant setting is allowed~* History of another malignancy (except subjects who have been disease free for 3 years or with a history of completely resected non-melanoma skin cancer)~* Known HIV, HBV, HCV infection (except chronic or cleared HBV and HCV infection which will be allowed)~* Brain metastases (except if all known lesions were previously treated with surgery or stereotactic radiosurgery and lesions, if still present, are confirmed stable for \>= 12 weeks prior to randomisation or if no longer present are confirmed no evidence of disease for \>= 12 weeks, and are asymptomatic with no corticosteroid requirements for \>= 4 weeks prior to randomisation, and no enzyme inducing anticonvulsants for \>= 4 weeks prior to randomisation~* History or evidence of cardiovascular risk (LVEF \< LLN; QTcB \>= 480 msec; blood pressure or systolic \>=140 mmHg or diastolic \>= 90 mmHg which cannot be controlled by anti-hypertensive therapy)~* History or current evidence/risk of retinal vein occlusion (RVO) or central serous retinopathy (CSR)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dabrafenib plus Trametinib (Type: EXPERIMENTAL): BRAF inhibitor plus MEK inhibitor
- Vemurafenib (Type: ACTIVE_COMPARATOR): BRAF inhibitor

Based on this trial design, predict the completion outcome and termination type (if applicable).